Secondary leukemogenesis in the context of T-cell based immunotherapies project
An SWG Grant-supported project initiated by the EHA SWG on Immune Therapies for Hematologic Disorders.
Project lead
Project background and aims
Secondary leukemias represent a critical safety concern for T-cell-based immunotherapies in hematologic cancers.
This EHA/SWG-funded project will explore the potential link between T-cell therapy-induced inflammation and the acceleration of pre-existing clonal hematopoiesis of indeterminate potential (CHIP) within the hematopoietic niche.
We will examine the landscape of CHIP mutations in patients with multiple myeloma and B-cell lymphomas (aim 1) and will track CHIP clonal expansion over time during CAR T and bispecific antibody treatment (aim 2).
Funding through the EHA-SWG network offers a unique and invaluable opportunity to expand this study across a vast network of academic centers within the European hematology community.